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System A-mediated amino acid transport across the placenta is important for the supply of neutral amino
acids needed for fetal growth. All three system A subtypes (SNAT1, 2, and 4) are expressed in human pla-
cental trophoblast suggesting there is an important biological role for each. Placental system A activity
increases as pregnancy progresses, coinciding with increased fetal nutrient demands. We have previously
shown SNAT4-mediated system A activity is higher in ﬁrst trimester than at term, suggesting that SNAT1
and/or SNAT2 are responsible for the increased system A activity later in gestation. However, the relative
contribution of each subtype to transporter activity in trophoblast at term has yet to be evaluated. The
purpose of this study was to identify the predominant subtype of system A in cytotrophoblast cells iso-
lated from term placenta, maintained in culture for 66 h, by: (1) measuring mRNA expression of the three
subtypes and determining the Michaelis–Menten constants for uptake of the system A-speciﬁc substrate,
14C-MeAIB, (2) investigating the contribution of SNAT1 to total system A activity using siRNA. Results:
mRNA expression was highest for the SNAT1 subtype of system A. Kinetic analysis of 14C-MeAIB uptake
revealed two distinct transport systems; system 1: Km = 0.38 ± 0.12 mM, Vmax = 27.8 ± 9.0 pmol/mg
protein/20 min, which resembles that reported for SNAT1 and SNAT2 in other cell types, and system 2:
Km = 45.4 ± 25.0 mM, Vmax = 1190 ± 291 pmol/mg protein/20 min, which potentially represents SNAT4.
Successful knockdown of SNAT1 mRNA using target-speciﬁc siRNA signiﬁcantly reduced system A activ-
ity (median 75% knockdown, n = 7). Conclusion: These data enhance our limited understanding of the rel-
ative importance of the system A subtypes for amino acid transport in human placental trophoblast by
demonstrating that SNAT1 is a key contributor to system A activity at term.
 2010 Elsevier Inc. Open access under CC BY license.1. Introduction
It is well established that system A-mediated transport of ami-
no acids across the placenta is important for maintaining normal
fetal growth [1]. In humans, placental system A activity increases
as pregnancy progresses [2], coinciding with increased fetal nutri-
ent demands, and is downregulated in pregnancies complicated by
fetal growth restriction (FGR) [3,4]. System A is a Na+-dependent
amino acid transporter that actively transports small, zwitterionic,
neutral amino acids with short unbranched side chains and the
synthetic amino acid a-(methylamino)isobutyric acid (MeAIB)
[5]. This non-metabolised amino acid analogue has a speciﬁc afﬁn-
ity for system A [6] and has been used extensively to study this
transport system in the placenta [4,7–9].
Molecular characterisation has revealed there are three highly
homologous protein subtypes of system A; SNAT1, SNAT2, and
SNAT4 [10,11] encoded by SLC38A1, 2 and 4, respectively. Charac-.uk (M. Desforges).
Y license.terisation of these subtypes has revealed that SNAT1 and 2 are
kinetically very similar [12–14], whereas SNAT4 has a relatively
lower afﬁnity for neutral amino acids and also interacts with cat-
ionic amino acids in a Na+-independent manner such that it resem-
bles system y+L [15,16]. Each of the subtypes are expressed in
human placenta [17,18], but their relative contribution to system
A-mediated amino acid transport across gestation of normal preg-
nancy, or in FGR, is poorly understood.
The gestational changes in human placental system A activity,
and the reduction in FGR, cannot be explained simply by altered
expression of the three transporter subtypes [17–19], suggesting
an important locus for regulation of system A is at the level of
transporter activity. We have previously shown that the contribu-
tion of SNAT4 to placental system A activity is relatively high dur-
ing ﬁrst trimester and decreases towards term [18]. This leads us to
propose that at later stages of pregnancy, SNAT1 and/or SNAT2 are
responsible for the increase in placental system A activity that oc-
curs across gestation.
The aims of our study were to identify the predominant subtype
of system A in term human placenta by: (1) measuring mRNA
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constants for MeAIB uptake in cytotrophoblast cells isolated from
term placenta and maintained in primary culture, (2) determining
the contribution of SNAT1 to total system A activity in cytotropho-
blast cells using siRNA technology.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma–Aldrich Co. Ltd.
(Poole, UK) or VWR International (Lutterworth, UK) unless other-
wise stated.
2.2. Primary cytotrophoblast cell isolation and culture
Term placentae (38–40 weeks gestation) were collected with
written informed consent and in accordance with Local Ethics
Committee approval following Caesarean section or vaginal deliv-
ery from uncomplicated singleton pregnancies. Cytotrophoblast
cells were then isolated using an adaptation of the method devel-
oped by Kliman et al. [20] as described previously [21]. Isolated
cells were plated in culture medium (Dulbecco’s modiﬁed Eagle’s
medium and Ham’s F-12 1:1, 10% heat inactivated Fetal Calf Serum,
0.6% glutamine, and antibiotics; 1% gentamicin, 0.2% penicillin,
0.2% streptomycin) onto 35-mm culture dishes (Nunc), at a density
of 2–2.5  106, and were maintained in primary culture for 66 h at
37 C in a humidiﬁed incubator (95% air/5% CO2).
2.3. Quantitative PCR analysis of SNAT subtype mRNA expression in
cytotrophoblast cells
Following 66 h in culture, cyotrophoblast cells were lysed and
total RNA extracted using Absolutely RNA Microprep Kit (Strata-
gene, USA). RNA was quantiﬁed using Quant-iT Ribogreen kit
(Molecular Probes) and 100 ng of total RNA from each sample re-
verse transcribed using AfﬁnityScript cDNA synthesis kit with ran-
dom primers (Stratagene, USA). mRNA for SNAT1 (SLC38A1), SNAT2
(SLC38A2), SNAT4 (SLC38A4), and b-actin were quantiﬁed in a 1:10
dilution of the cDNA samples by QPCR using Stratagene’s MX3000P
real time PCR machine and Brilliant SYBR Green I QPCR mastermix
(Stratagene, USA), with 5-carboxy-x-rhodamine as a passive refer-
ence dye. Primers (MWG-Biotech) for SLC38A1, SLC38A2 and
SLC38A4were used at a ﬁnal concentration of 300 nM, and for b-ac-
tin at 200 nM as previously described [17,22]. mRNA were quanti-
ﬁed against standard curves generated from either human liver
RNA (Ambion Inc., Cambridgeshire) for SLC38A4, or human refer-
ence total RNA (Stratagene, La Jolla, USA) for other genes. Levels
of SNAT subtype mRNA expression in cytotrophoblast cell samples
were compared statistically using a non-parametric paired test,
with a p value of <0.05 considered signiﬁcant.
2.4. Determining the Km and Vmax of MeAIB uptake by primary
cytotrophoblast cells
Following 66 h in culture, primary cytotrophoblast cells were
washed free of cell culture medium using Tyrode’s buffer
(135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM
Hepes, 5.6 mM glucose, pH 7.4) and the uptake of radiolabelled
14C-MeAIB (10 nM in Tyrode’s buffer), in the presence of varying
concentrations of unlabelled MeAIB (10–25 mM in Tyrode’s buf-
fer), was measured in duplicate at 37 C. Uptake was terminated
after 20 min, a time previously conﬁrmed to be at initial rate (data
not shown), by washing cells in 25 ml ice cold Tyrode’s buffer over
1 min. Cells were then lysed in 1 ml 0.3 M NaOH and the lysatecounted for b radiation. Cell lysate protein content (mg) was deter-
mined using the method of Bradford [23] using a commercial kit
(Bio-Rad Laboratories Ltd.: Hemel Hampstead, UK). Uptake of
radiolabelled MeAIB is expressed as pmol per mg protein over
20 min. Kinetic modelling of MeAIB competitive inhibition curves
was achieved using the SIMFIT computer program (SIMFIT version
6.0.18; W.G. Bardsley, University of Manchester; http://www.sim-
ﬁt.man.ac.uk) which supports curve ﬁtting of data with discrimina-
tion of kinetically distinct transporters by determining the best-ﬁt
to the Michaelis–Menten equation. The program assumes the ki-
netic transformation process is the same whether the substrate is
labelled or not, so if the radiolabelled substrate is ﬁxed ([hot]),
the initial rate of uptake (y) will be proportional to the concentra-
tion of unlabelled substrate ([cold]) added, allowing isotope dis-
placement kinetics to be modelled to the following equation:
y ¼ d½hot
dt
¼ Vmax1
Km1 þ ½cold þ
Vmax2
Km2 þ ½cold ð1Þ
where [hot] = concentration of radiolabelled substrate, [cold] = con-
centration of unlabelled substrate, Km = Michaelis constant and
Vmax = maximal velocity. The best ﬁt to the data was determined
by the F test, comparing the closeness of ﬁt (weighted sum of
squares of the variance) against the number of parameters in the
model.
2.5. Transfection of primary cytotrophoblast cells with siRNA
Initial experiments using ﬂuorescently-labelled non-targeting
siRNA sequences to optimise transfection conditions, and Actino-
mycin D to establish the half-life of SLC38A1mRNA (approximately
6 h, n = 3), led to a protocol in which after 18 h in culture, cytotro-
phoblast cells were transfected with 50 or 100 nM SNAT1-speciﬁc
siRNA (Qiagen) using DharmaFECT2 transfection reagent (Dharma-
con) as described previously [22]. Initially, four different SNAT1-
speciﬁc siRNAs were tested and here we present data using the
construct which most efﬁciently silenced SLC38A1 (target se-
quence: 50-CAGAGCTAAATTCAACAATAA-30). Cytotrophoblast cells
transfected with non-targeting siRNA (Invitrogen) and cells ex-
posed to DharmaFECT2 only (i.e. mock transfected) were included
as controls.
2.6. Conﬁrmation of target-speciﬁc knockdown
Forty-eight hours post-transfection, cells were lysed and total
RNA was extracted, quantiﬁed and reverse transcribed as described
above. SLC38A1, SLC38A2, SLC38A4 and b-actin mRNA expression
was analysed by quantitative PCR to conﬁrm target-speciﬁc knock-
down. Data were analysed by Wilcoxon-signed rank test following
normalisation of mRNA expression to the mock-transfected control
sample for the corresponding experiment.
2.7. System A activity measurements following SNAT1 knockdown
Forty-eight hours post-transfection, Na+-dependent uptake of
14C-MeAIB (10 nM) by control and transfected cytotrophoblast
cells was measured over 20 min. Uptake of 14C-MeAIB was carried
out at 37 C in either control or Na+-free Tyrode’s buffer (135 mM
choline chloride replaced NaCl, pH 7.4) using the same procedure
as described above. The Na+-dependent component of 14C-MeAIB
uptake, representing system A-speciﬁc uptake, was calculated by
subtracting 14C-MeAIB uptake in the absence of Na+ from uptake
in the presence of Na+. Data were analysed by Wilcoxon-signed
rank test following normalisation to Na+-dependent 14C-MeAIB up-
take by the corresponding control sample (i.e. untransfected) for
each experiment.
132 M. Desforges et al. / Biochemical and Biophysical Research Communications 398 (2010) 130–1343. Results and discussion
3.1. Comparison of SNAT subtype mRNA expression levels in term
cytotrophoblast cells
Standard curve efﬁciencies and Ct values were comparable for
SLC38A1 and SLC38A2 QPCR (efﬁciencies: 83.4% and 83.5%, respec-
tively). This allowed normalisation of SLC38A1 and SLC38A2 mRNA
expression in each sample to corresponding b-actin mRNA expres-
sion, thereby correcting for any differences in reverse transcription
efﬁciency between the samples. Fig. 1A demonstrates SLC38A1
mRNA expression in cytotrophoblast cells was signiﬁcantly higher
than SLC38A2mRNA expression. SLC38A4mRNAwas detected in all
samples but often at a quantity below the lowest standard
(0.78 ng). Therefore, SLC38A4 mRNA data are not shown as levels
were too low to accurately quantify. This observation was not
unexpected as we have previously found that SLC38A4mRNA levels
in villous tissue homogenates from some term placentas are below
the levels of detection using QPCR [17].
3.2. Kinetics of MeAIB transport by term cytotrophoblast cells
Kinetic modelling by non-linear regression analysis of the inhi-
bition by unlabelled MeAIB of 14C-MeAIB uptake into primary cyto-
trophoblast cells (Fig. 1B), revealed that the model of best ﬁt was to
a two saturable transporter model (F test, p < 0.05) and this trend
was consistent for each of the ﬁve individual cytotrophoblast
isolates (r2P 0.83). The kinetic characteristics for each transport
system were; system 1: Km = 0.38 ± 0.12 mM, Vmax = 27.8 ± 9.0
pmol/mg protein/20 min, and system 2: Km = 45.4 ± 25.0 mM,
Vmax = 1190 ± 291 pmol/mg protein/20 min. The kinetic character-
istics of the two systems identiﬁed indicate there is a high afﬁnity,
low capacity transport system for MeAIB in these cells (system 1)
as well as a low afﬁnity, high capacity transport system (system
2). As all three system A subtypes are expressed by these cells, it
is possible that two have a very similar afﬁnity for MeAIB. Experi-
ments using human retinal pigment epithelial (HRPE) cells manip-
ulated to express the individual system A subtypes revealed Km
values for SNAT1, SNAT2 and SNAT4 of 0.89, 0.39, 6.7 mM, respec-
tively [12,13,15]. Bearing in mind the potential differences in intra-
cellular regulatory factors and/or plasma membrane composition
between cell types which could inﬂuence transporter kinetics,
the Km value of system 1 determined here is reasonably similar
that reported for SNAT1 and SNAT2 in HRPE cells and therefore,
could represent transport by both these system A subtypes. WeFig. 1. (A) Box and whisker plots to show SLC38A1 and A2 mRNA expression in term cyt
interval between the 25th and 75th percentile, the whiskers represent the range, and t
Kinetic modelling of 14C-MeAIB uptake in cytotrophoblast cells, using non-linear regressio
A two-site model was preferred (F test, p < 0.05). Data are shown as median and interqupropose that system 2 represents SNAT4 despite the Km value
being almost 7-fold higher than that reported for SNAT4 in HRPE
cells. Again, this could reﬂect differences in lipid environment of
the transporter between the cell types. Indeed, the Km for taurine
transport by system b varies quite considerably between different
cell types from the same species (in some cases over 10-fold) and
between particular cell types isolated from different species [24].
3.3. SNAT1-speciﬁc knockdown in primary cytotrophoblast cells
Following transfection of cytotrophoblast cells with 50 and
100 nM SNAT1-speciﬁc siRNA, SLC38A1 mRNA expression was sig-
niﬁcantly reduced compared to mock-transfected cells (Fig. 2A).
siRNA (50 and 100 nM) were equally effective in eliciting knock-
down of SLC38A1 mRNA, indicating the lower concentration was
sufﬁcient to achieve maximal knockdown. Transfection of cells
with non-targeting siRNA did not affect SLC38A1mRNA eliminating
the possibility that simply delivering siRNA into the cell causes re-
duced SLC38A1 mRNA expression (Fig. 2A). SLC38A2 and b-actin
mRNA expression was unaffected following transfection of cells
with 100 nM SNAT1-speciﬁc siRNA (Fig. 2B and C) conﬁrming spec-
iﬁcity of the siRNA for its target.
3.4. Contribution of SNAT1 to system A activity in term
cytotrophoblast cells
Knockdown of SLC38A1 mRNA in cytotrophoblast cells was
accompanied by a signiﬁcant reduction in system A activity, mea-
sured as Na+-dependent uptake of 14C-MeAIB (Fig. 3). In common
with the mRNA data, transfection with 50 nM SNAT1-speciﬁc siR-
NA produced a similar effect to transfection with 100 nM siRNA,
further conﬁrming maximal knockdown was achieved using the
lower concentration of siRNA. As shown in Table 1, 50 nM
SNAT1-speciﬁc siRNA did not affect the Na+-independent compo-
nent of 14C-MeAIB uptake (i.e. that not mediated by system A). Sys-
tem A activity in cytotrophoblast cells was unaffected following
treatment with DharmaFECT2 transfection reagent or transfection
with non-targeting siRNA (Fig. 3).
Data presented in Fig. 2A demonstrate that complete knock-
down of the SNAT1 transporter mRNA was not achievable using
50 nor 100 nM SNAT1-speciﬁc siRNA as some residual expression
remained. Therefore, it is possible that a small proportion of the
system A activity observed in cells transfected with SNAT1-speciﬁc
siRNA (shown in Fig. 3) represents SNAT1-mediated MeAIB trans-
port, with the remaining majority representing SNAT2-mediatedotrophoblast cells relative to b-actin mRNA expression (n = 7). The box denotes the
he line inside the box shows the median; *p < 0.01, Wilcoxon-signed rank test. (B)
n analysis, with one-site (dashed line) and two-site (solid line) binding components.
artile range (n = 5).
Fig. 2. (A) SLC38A1, (B) SLC38A2, and (C) b-actin mRNA expression in cells transfected with non-targeting (NT) or SLC38A1-specﬁc (SNAT1) siRNA relative to corresponding
mock transfected cytotrophoblast cells (dashed line at 100%). Median and interquartile range; **p < 0.01 vs 100%, Wilcoxon-signed rank test.
Fig. 3. System A activity, measured as Na+-dependent 14C-MeAIB uptake, by mock transfected cytotrophoblast cells and cells transfected with non-targeting (NT) or SLC38A1-
speciﬁc (SNAT1) siRNA. System A activity is expressed relative to the corresponding untransfected control (dashed line at 100%). Median and interquartile range; *p < 0.05 vs
100%, Wilcoxon-signed rank test.
Table 1
Components of 14C-MeAIB uptake by transfected cytotrophoblast cells.
Median (range) MeAIB uptake (% of untransfected control)
Total Na+-independent Na+-dependent
50 nM NT 91.5 (51.1–127.8) 81.34 (54.1–180.3) 93.5 (49.9–126.7)
50 nM SNAT1 47.8 (25.2–70.1)* 113.7 (81.5–222.8) 25.9 (13.5–62.9)*
* p < 0.05 vs 100%, Wilcoxon-signed rank test.
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based on the relatively low levels of SLC38A4 expression in cytotro-
phoblast cells and the lower afﬁnity of SNAT4 for MeAIB compared
to SNAT2 [12,15].
In central neurons, the selectivity of SNAT1 for MeAIB is less
than one-tenth of that for its preferred substrates, alanine or gluta-mine [25], and therefore, MeAIB is perhaps not an ideal substrate
for use in experiments designed to investigate SNAT1 activity.
However, as MeAIB is a speciﬁc substrate for system A and, in
the present study, MeAIB was the only substrate available, it would
have been readily transported by any system A subtype. Consider-
ing the afﬁnity of SNAT2 in HRPE for MeAIB is similar to that for its
preferred substrate, alanine [12], it has perhaps been reasonable to
assume that system A activity measurements previously made in
placenta using MeAIB would mainly represent SNAT2-mediated
transport. However, our data show that under the conditions of
these experiments, SNAT1 made the major contribution to system
A activity in cytotrophoblast cells isolated from term human
placenta.
Reduced expression and/or activity of SNAT1 in the placenta
could, therefore, underlie the compromised system A activity in
placentas from pregnancies complicated with FGR [3]. The regula-
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cases of FGR are currently under investigation and there is evi-
dence to suggest these include oxygen tension, substrate levels,
as well as some cytokines, hormones and growth factors [1,26].
Each of these factors are altered in pregnancy complications asso-
ciated with placental pathology and could, therefore, inﬂuence sys-
tem A activity through differential effects on the SNAT subtypes.
4. Conclusions
Our data contribute to the limited understanding of the relative
importance of the three system A subtypes for amino acid trans-
port in human placenta by demonstrating that knockdown of the
SNAT1 subtype in primary cytotrophoblast cells signiﬁcantly re-
duces MeAIB uptake, thereby suggesting that SNAT1 is a key con-
tributor to term placental system A activity. However, all three
subtypes are present in placenta, which implies there is an impor-
tant biological role for each. Accumulating evidence suggests there
is differential regulation of the three SNAT subtypes [27–29].
Therefore, future studies investigating system A in the placenta
should continue to focus on the differential regulation of the three
SNAT subtypes in parallel to transporter activity measurements.
This will help to further elucidate the relative roles of each subtype
for system A-mediated amino acid transport and facilitate our
understanding of the processes involved in those alterations asso-
ciated with pathological pregnancy conditions.
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